Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source

Joseph Kamtchum-Tatuene 1*, Ali Z. Nomani 2, Sarina Falcione 2, Danielle Munsterman 2, Gina Sykes 2, Twinkle Joy 2, Elena Spronk 2, Maria Isabel Vargas 3 and Glen C. Jickling 2

1 Faculty of Medicine and Dentistry, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada, 2 Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 3 Division of Neuroradiology, Department of Radiology and Medical Imaging, Geneva University Hospital, Geneva, Switzerland

Embolic stroke of unknown source (ESUS) represents one in five ischemic strokes. Ipsilateral non-stenotic carotid plaques are identified in 40% of all ESUS. In this narrative review, we summarize the evidence supporting the potential causal relationship between ESUS and non-stenotic carotid plaques; discuss the remaining challenges in establishing the causal link between non-stenotic plaques and ESUS and describe biomarkers of potential interest for future research. In support of the causal relationship between ESUS and non-stenotic carotid plaques, studies have shown that plaques with high-risk features are five times more prevalent in the ipsilateral vs. the contralateral carotid and there is a lower incidence of atrial fibrillation during follow-up in patients with ipsilateral non-stenotic carotid plaques. However, non-stenotic carotid plaques with or without high-risk features often coexist with other potential etiologies of stroke, notably atrial fibrillation (8.5%), intracranial atherosclerosis (8.4%), patent foramen ovale (5–9%), and atrial cardiopathy (2.4%). Such puzzling clinical associations make it challenging to confirm the causal link between non-stenotic plaques and ESUS. There are several ongoing studies exploring whether select protein and RNA biomarkers of plaque progression or vulnerability could facilitate the reclassification of some ESUS as large vessel strokes or help to optimize secondary prevention strategies.

Keywords: stroke, carotid stenosis, carotid plaque, biomarkers, atherosclerosis

INTRODUCTION

Ischemic stroke is considered cryptogenic when no definite cause is identified during the baseline etiological workup (1). According to the Cryptogenic Stroke/Embolic Stroke of Undetermined Source International Working Group, the baseline etiological workup should include brain imaging with computed tomography (CT) or magnetic resonance imaging (MRI), assessment of the heart rhythm with 12-lead ECG and continuous cardiac monitoring for at least 24 h with automated rhythm detection, transthoracic cardiac ultrasound, and imaging of cervical and intracranial vessels supplying the infarcted brain region (using CT, MRI, conventional angiography, or ultrasonography) (2).
Cryptogenic strokes represent ~30% of all ischemic strokes. They could be further classified into three subgroups: stroke with no cause despite complete baseline workup, stroke with multiple possible underlying causes, and stroke with incomplete baseline workup (3). In the subgroup of cryptogenic strokes with complete workup, embolic stroke of unknown source (ESUS) is a clinical construct referring to non-lacunar ischemic strokes (size > 1.5 cm on CT or > 2.0 cm on diffusion MRI) of presumable embolic origin (superficial/cortical brain lesion) despite the absence of any obvious sources of cardiac or arterial embolism (e.g., atrial fibrillation, carotid, or intracranial stenosis > 50%) (Figure 1) (2). ESUS represent ~17% of all ischemic strokes with a recurrent stroke rate of 4.5% per year despite antithrombotic therapy (4–6).

The definition of ESUS was based on the assumptions that cryptogenic strokes may be related to covert atrial fibrillation and that a relationship between non-stenotic atherosclerotic plaques (causing <50% stenosis) and stroke was unlikely. However, there is now evidence to suggest that ESUS represents a heterogeneous group including patients with various other potential causes of stroke besides atrial fibrillation (7–9). Such causes include atrial cardiopathy (10), patent foramen ovale (PFO) (11), cancer (12), and non-stenotic plaques affecting the aortic arch or carotid, vertebral, or intracranial arteries (7, 13, 14). Atrial cardiopathy is a concept referring to a dysfunction of the left atrium that is thought to favor and precede the onset of atrial fibrillation and its eventual detection by electrocardiographic devices. The diagnosis is based on the identification of imaging markers (e.g., left atrial enlargement, spontaneous echocontrast in the left atrium or the left atrial appendage, atrial fibrosis with delayed gadolinium enhancement on MRI), electrocardiographic markers (e.g., paroxysmal supraventricular tachycardia, increased P-wave terminal force in V1, interatrial block, prolonged PR), and blood biomarkers (e.g., N-terminal pro-brain natriuretic peptide, highly sensitive cardiac troponin T) (10).

Non-stenotic carotid plaques are found in 40% of patients with ESUS and 10–15% of patients with ESUS have mild stenosis (20–49%) (2, 15–17). Here we review the evidence supporting the relationship between non-stenotic carotid plaques with high-risk features and stroke in patients with ESUS. We present the remaining challenges in the process of formally establishing the causal link between non-stenotic plaques and ESUS, notably those related to the identification of blood biomarkers of vulnerable plaque. Finally, we discuss the management of non-stenotic carotid plaques in patients with ESUS and highlight areas for future research.

**NON-STENOTIC CAROTID PLAQUES AS A POTENTIAL CAUSE OF ESUS**

The relationship between non-stenotic carotid plaques and ESUS is supported by a set of three clinical observations.

First, in patients with ESUS, carotid plaques are more prevalent on the side of the stroke than on the contralateral side. In a cross-sectional study of 85 patients with ESUS, non-stenotic carotid plaques thicker than 3 mm were present in 35% of ipsilateral carotid arteries vs. 15% of the contralateral carotid arteries (18). A similar finding was observed in a review of 138 ESUS cases from the prospec-tive multicenter INTERRSeCT study (The Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography). The investigators found a non-stenotic carotid plaque ipsilateral to the stroke in 29.2% of patients and contralateral to the stroke in 18.7% (17).

Second, in patients with ESUS, there is a lower incidence of atrial fibrillation detected during follow-up in patients with ipsilateral non-stenotic carotid plaques than in those without, thus suggesting that non-stenotic carotid plaques may be related to the stroke. In 777 participants of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial who were followed up for a median of 2 years, the incidence of atrial fibrillation was 2.9 per 100 person-years in patients with ipsilateral non-stenotic carotid plaques vs. 5.0 per 100 person-years in those without (overall rate: 8.5 vs. 19.0%; adjusted hazard ratio: 0.57, 95% CI 0.37–0.84) (15).

Third, plaques with high-risk features are more prevalent on the side of the stroke in patients with ESUS. In a meta-analysis of 8 studies enrolling 323 patients with ESUS, plaques with high-risk features were present in 32.5% of the ipsilateral carotid arteries vs. 4.6% of the contralateral carotid arteries. More specifically, the odds of finding a non-stenotic carotid plaque with a ruptured fibrous cap in the ipsilateral vs. the contralateral carotid artery was 17.5, reinforcing the idea that non-stenotic carotid plaques should not be considered as benign coincidental findings in patients with ESUS (13).

High-risk plaques have features on brain or vascular imaging that are associated with a higher risk of stroke in patients with either symptomatic or asymptomatic carotid atherosclerosis, independent of the grade of stenosis (19–24). The most common high-risk plaque features are echolucency, impaired cerebrovascular reserve, intraplaque hemorrhage (Figure 1), silent brain infarcts, lipid-rich necrotic core, large juxtalaminal black hypoechoic area, large plaque volume, plaque thickness, microembolic signals, mural thrombus, neovascularization, plaque irregularity, plaque inflammation or hypermetabolism, thin or ruptured fibrous cap, and ulceration (19, 21, 25–31). The American Heart Association combines some of these features to derive a classification of atherosclerotic plaques into 6 types reflecting increasing instability and risk of cardiovascular events (Table 1) (32–37). On average, high-risk plaque features are three times more prevalent in patients with symptomatic vs. asymptomatic carotid stenosis (OR = 3.4, 95% CI: 2.5–4.6) (19). They are detected using various vascular imaging modalities (Table 2). To date, there are no data on the risk of recurrent stroke associated with each of the high-risk features in patients with ESUS. Analysis of secondary outcome data from the Carotid Plaque Imaging in Acute Stroke study (CARIAS; NCT01284933) might help to address this knowledge gap (35, 39).
**CHALLENGES OF ESTABLISHING CAUSAL LINK WITH STROKE**

**Puzzling Clinical Associations**

Although studies of high-risk features have provided evidence of an association between non-stenotic carotid plaques and brain infarction in patients with ESUS, establishing causality remains challenging in most cases. The dilemma rests on four clinical observations. First, high-risk features are often found in plaques in the absence of related clinical symptoms (19, 40). In a meta-analysis of eight studies enrolling 323 patients with ESUS, a non-stenotic carotid plaque with high-risk features was identified in the contralateral carotid artery in 4.6% of cases (95% CI: 0.1–13.1) (13). Likewise, in a meta-analysis of 64 studies enrolling 20,571 patients with asymptomatic carotid stenosis of various grades, 26.5% of patients were found to have at least one high-risk plaque feature (95% CI: 22.9–30.3). The highest prevalence was observed for neovascularization (43.4%, 95% CI: 31.4–55.8) and the lowest for mural thrombus (7.3%, 95% CI: 2.5–19.4). On average, intraplaque hemorrhage was found in 1 out of 5 patients (19). Second, high-risk plaque features are not specific for symptomatic carotid plaques. In a meta-analysis of data from 20 prospective studies enrolling 1,652 patients with symptomatic carotid stenosis, high-risk plaque features were identified in <1 in 2 patients (43.3%, 95% CI: 33.6–53.2) (19). Third, in patients with stroke, there is an association between the presence of high-risk plaque features and atrial fibrillation. In a study of 68 patients with embolic stroke, including 45 ESUS, the presence of high-risk plaque features on carotid ultrasound (ulceration, thickness ≥ 3 mm, and echolucency) was independently associated with detection of atrial fibrillation on admission or during follow-up (OR = 4.5, 95% CI: 1.0–19.6) (41). Fourth, in some patients with ESUS diagnosed using the current clinical definition, non-stenotic carotid plaques often coexist with other potential causes of stroke, including atrial fibrillation (8.5%) (15), intracranial atherosclerosis (8.4%) (42), PFO (5–9%) (43, 44), and atrial cardiopathy (2.4%) (45).

**Lack of Reliable Biomarkers**

The identification of an ipsilateral non-stenotic carotid plaque with or without high-risk features is not sufficient to reclassify ESUS as stroke due to large vessel disease. Further research is,
### TABLE 1 | American Heart Association comprehensive morphological classification scheme for atherosclerotic lesions (32–34).

| Plaque type                              | Lipid rich necrotic core | Fibrous cap | Calcification | Erosion/rupture | Intraplaque hemorrhage | Thrombus | Regression to normal |
|------------------------------------------|--------------------------|-------------|---------------|-----------------|------------------------|----------|----------------------|
| **Type I (Initial lesion)**              |                          |             |               |                 |                        |          | Possible             |
| Initial lesion, accumulation of smooth muscle cells and isolated foam cells, absence of a necrotic core. | Absent                   | Absent      | Absent         | Absent            | Absent                | Absent   | Possible             |
| **Type II (Intimal xanthoma)**           |                          |             |               |                 |                        |          | Possible             |
| Multiple layers of foam cells, previously referred to as “fatty streak” | Absent                   | Absent      | Absent         | Absent            | Absent                | Absent   | Possible             |
| **Type III (pre-atheroma)**              |                          |             |               |                 |                        |          | Possible             |
| Smooth muscle cells in a proteoglycan-rich extracellular matrix, multiple layers of foam cells, non-confluent extracellular lipid pools | Absent                   | Present (ill-defined) | Absent         | Absent            | Absent                | Absent   | Possible             |
| **Type IV (atheroma)**                   |                          |             |               |                 |                        |          | Not possible          |
| Confluent extracellular lipids           | Present (well-formed)    |             | Present (well-defined) | Absent         | Absent                | Absent   | Not possible          |
| **Type Va (Fibroatheroma)**              |                          |             |               |                 |                        |          | Not possible          |
| Confluent extracellular lipids with prominent proliferative fibromuscular layer | Present (thick)          |             | Possible<sup>a</sup> | Absent         | Absent                | Absent   | Not possible          |
| **Type VI (Complicated atheroma)<sup>b</sup>** |                          |             |               |                 |                        |          | Not possible          |
| Inflammatory lesion with at least one high-risk feature | Present (large)          |             | Present (thin or eroded) | Possible (partial calcification) | Possible (Via if present alone) | Possible (Vib if present alone) | Not possible |

<sup>a</sup>The plaque is assigned category Vb if predominantly calcified (fibro-calcific) or category Vc if predominantly fibrous (collagen-rich atheroma with smaller lipid core).

<sup>b</sup>The plaque is assigned category VIabc if erosion/ulceration, intraplaque hemorrhage and luminal thrombus are present concurrently.
The following high-risk features are used less often: juxta-luminal black hypoechoic area and plaque volume assessed by ultrasound, plaque inflammation measured by standardized (18) F-FDG uptake on positron emission tomography–computed tomography, carotid temperature assessed by microwave radiometry.

For simplicity, the description of each high-risk feature is based on its appearance on the imaging modality of choice.

The sound threshold and the number of MES for a positive examination is variable across studies. AHA, American Heart Association; BOLD, blood oxygen level-dependent; CEUS, contrast-enhanced ultrasound; CI, confidence interval; CT, computed tomography; DCE, dynamic contrast-enhanced; ESUS, embolic stroke of undetermined source; FLAIR, fluid-attenuated inversion recovery; MCA, middle cerebral artery; MRI, Magnetic Resonance Imaging; T1W, T1-weighted imaging; T2W, T2-weighted imaging; TCD, transcranial Doppler ultrasound; and 3D-TOF, 3-dimensional time of flight.

Therefore, needed to determine whether combination of vascular imaging findings, clinical data, and candidate biomarkers of plaque progression/instability or atheroembolism (46–82) into multiparameter scores could improve the ability to (1) establish a causal link between ESUS and a non-stenotic carotid plaque, (2) predict plaque progression or stroke recurrence, and (3) select
patients who might benefit from adjuvant anti-inflammatory and lipid-lowering therapies as briefly discussed in the next section. Some biomarkers of plaque progression and instability that warrant further investigation specifically in patients with ESUS are presented in Table 3. There are several ongoing projects exploring biomarkers in patients with ESUS or cryptogenic stroke, notably the Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome study (SECRETO, NCT01934725) (95), the Carotid Plaque Imaging in Acute Stroke study (CAPIAS, NCT01284933) (35), and the Biomarkers of Acute Stroke Etiology study (BASE, NCT02014896) (96). Efforts to establish a causal relationship between non-stenotic carotid stenosis and ESUS using biomarkers and multimodal vascular imaging in well-phenotyped prospective cohorts will also benefit from research aiming to identify alternative causes of stroke in patients with ESUS (14, 68, 97–104).

**CHALLENGES OF SECONDARY STROKE PREVENTION**

As a result of the challenges to determine the root cause of an ESUS, the optimal treatment strategy for patients with ESUS remains unclear, and a tailored approach would likely be the most appropriate (9). In this section, we briefly describe the strategies that have been explored so far and discuss possible future directions.

**Dual Antiplatelet Therapy and Antiplatelet Switch**

Following the results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) (105) and the Clopidogrel in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events (CHANCE) (106) trials, patients with ESUS are treated with Aspirin-based dual antiplatelet therapy for 21 days provided that their baseline NIHSS is low. After 3 weeks, patients ideally return to single antiplatelet therapy and switching from Aspirin to Clopidogrel is considered in patients who had an ESUS while on Aspirin (107). A meta-analysis of data from CHANCE and POINT showed that extending the treatment beyond 3 weeks might increase the bleeding risk without additional benefit for secondary stroke prevention (108). Whether the presence of ipsilateral non-stenotic carotid plaque with or without high-risk features would modify the magnitude (absolute risk reduction) and duration (beyond 21 days) of the benefits derived from dual antiplatelet therapy in patients with ESUS remains unknown. In patients allergic to Clopidogrel and in carriers of a CYP2C19 loss of function allele, Ticagrelor might be an alternative according to findings of the Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA [acetylsalicylic acid] for Prevention of Stroke and Death (THALES) trial (109–112). The ongoing Clopidogrel with Aspirin in High-risk patients with Acute Non-Disabling Cerebrovascular Events II (CHANCE-2, NCT04078737) trial is evaluating the superiority of the Ticagrelor-Aspirin combination over Clopidogrel-Aspirin therapy in CYP2C19 loss of function carriers with minor stroke or transient ischemic attack (TIA) (113). There is currently no evidence supporting the use of dual antiplatelet therapies not containing Aspirin or triple antiplatelet therapies (with or without Aspirin) for secondary stroke prevention in patients with acute stroke or TIA (114).

**Anticoagulation**

The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA [Acetylsalicylic Acid] to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) and the Randomized Double-Blind Evaluation in Secondary Stroke Prevention Comparing The Efficacy Of Oral Thrombin Inhibitor Dabigatran Etxilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT-ESUS) trials have shown that universal full-dose oral anticoagulation is not an effective strategy to reduce the risk of stroke recurrence in patients with ESUS (5, 6). These results are likely explained by the heterogeneity of stroke mechanisms in patients with ESUS as discussed earlier, with atrial fibrillation being diagnosed in only 24.8% of cases at 24 months using insertable cardiac monitors (115). Moreover, there is no evidence that patients with ESUS and ipsilateral non-stenotic carotid plaques should be treated differently than those without plaques. In a subgroup analysis of data from 2,905 patients with non-stenotic carotid plaques enrolled in the NAVIGATE-ESUS trial, there was no difference between Rivaroxaban and Aspirin with respect to the prevention of ipsilateral ischemic stroke [Hazard ratio [HR] = 0.6, 95% CI: 0.2–1.9]. Major bleeding complications were significantly more frequent in patients taking anticoagulation (HR = 3.7, 95% CI: 1.6–8.7) (16).

In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, the combination Rivaroxaban-Aspirin (2.5 mg twice daily plus Aspirin 100 mg once per day) was superior to Aspirin alone (100 mg once daily) for the prevention of cardioembolic strokes (HR = 0.4, 95% CI: 0.2–0.8) and ESUS (HR = 0.3, 95% CI: 0.1–0.7) but there was no effect on the incidence of stroke due to moderate-to-severe carotid stenosis (HR = 0.9, 95% CI: 0.5–1.6) (116). Although these results suggest that the combination of Aspirin and low-dose Rivaroxaban could be an effective secondary stroke prevention strategy, they are not directly applicable to patients with ESUS since all patients with acute stroke (<1 month) were excluded from the trial due to the perceived higher risk of major intracranial bleeding (117). Furthermore, the baseline proportion of patients with non-stenotic carotid plaque, with or without high-risk features, was not reported. The prevalence of ipsilateral non-stenotic carotid plaque in participants diagnosed with ESUS during follow-up was also not reported.

According to currently available data, patients with ESUS and features of atrial cardiopathy, notably atrial enlargement, constitute the only subgroup that may benefit from anticoagulation (118). However, since these results are derived from a post-hoc analysis of the NAVIGATE-ESUS trial, they might not be used to justify universal prescription of anticoagulation until confirmation is obtained in dedicated trials. The ongoing Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA,
**TABLE 3** | Biomarkers of potential interest for the study of non-stenotic carotid plaques in ESUS.

| Biomarker | Type | Main source | Key evidence | Specific target of a drug previously tested in human trials | References |
|-----------|------|-------------|--------------|----------------------------------------------------------|------------|
| Lectin-like oxidized LDL receptor 1 (LOX-1) | Protein | Endothelial cells, smooth muscle cells, fibroblasts | In 4,702 participants from the Malmo Diet and Cancer Cohort, higher plasma levels of soluble LOX-1 were associated with higher risk of stroke during a mean follow-up of 16.5 years (HR = 1.3, 95% CI: 1.3–2.4). In 202 patients undergoing carotid endarterectomy, plasma levels of soluble LOX-1 were correlated with the plaque content of oxidized LDL, proinflammatory cytokines, and matrix metalloproteinases. | No | (46–49, 59, 75) |
| Omentin-1 | Protein | Visceral adipose tissue, stromal vascular cells, lung, heart, placenta, ovaries | In 173 patients with acute ischemic stroke, serum levels of omentin-1 were lower in subjects with unstable plaque (n = 38, echolucent, thin fibrous cap, ulcerated) than in those with stable plaques (median of 53 vs. 62 ng/mL). | No | (69) |
| Lipoprotein-associated phospholipase A2 (Lp-PLA2) | Protein | Monocytes, macrophages, T lymphocytes, and mast cells | In 1,946 participants of the Northern Manhattan study, there was a dose-response relationship between Lp-PLA2 mass and the risk of first-ever stroke due to large vessel atherosclerosis (HR = 1.4, 4.5, and 5.1 for quartiles 2, 3, and 4 compared with quartile 1 in multivariable survival analysis). | Yes (Darapladib) | (52, 53, 83) |
| Chitinase-3-like-1 (YKL-40) | Protein | Inflammatory cells | In 1,132 patients with carotid atherosclerotic plaques of various grades, higher levels of YKL-40 were associated with plaque instability (n = 655, echolucentcy) after adjusting for various demographic and cardiovascular risk factors (OR = 2.1 and 1.7 for quartiles 3 and 4, respectively). | No | (56, 59) |
| Granzyme B | Protein | T lymphocytes | In 67 patients with severe carotid stenosis undergoing revascularization, higher plasma levels of granzyme B were found in patients with unstable plaques (n = 16, echolucent) than in those with stable plaques (median of 492.0 vs. 143.8 pg/mL) | No | (57) |
| Vimentin | Protein | Endothelial cells, macrophages, and astrocytes | In 4,514 patients with carotid plaques in the Malmo Diet and Cancer Cohort, higher plasma levels of vimentin at baseline were associated with the incidence of ischemic stroke after a mean follow-up of 22 years (HR = 1.66, 95% CI: 1.23–2.25). | Yes (Withaferin-A) | (65, 84) |
| Macrophage chemoattractant protein (MCP-1/CCL2) | Protein | Monocytes | In the Athero-EXPRESS biobank, higher plaque levels of MCP-1 levels were found in symptomatic vs. asymptomatic plaques and in vulnerable vs. stable plaques. | No | (61) |
| Matrix metalloproteinase 9 (MMP9) | Protein | Macrophages, foam cells | Serum levels of MMP9 were higher in large artery atherosclerosis strokes (n = 26, 1,137 ng/mL) vs. cardioembolic strokes (n = 86, 517 ng/mL). MMP9 > 1,110 ng/mL had 85% sensitivity and 52% specificity for differentiating large vessel from cardioembolic strokes. | No | (59, 66) |
| Complement 5b-9 | Protein | Liver | In 70 patients with acute ischemic stroke, serum C5b-9 levels were higher in patients with unstable plaques (n = 37) than in those with stable plaques (median of 875 vs. 786 ng/mL). There was also a positive correlation with plaque burden and grade of stenosis. | Yes (Eculizumab) | (76, 85) |
| Interleukin 1β (IL-1β) | Protein | Monocytes, macrophages | A higher expression of IL-1β and other components of the NLRP3 inflammasome was observed in 30 plaques when compared with 10 healthy mesenteric arteries, both at the protein and the mRNA level. | Yes (Anakinra, Rilonacept, Canakinumab) | (77, 86–88) |
| Interleukin 6 (IL-6) | Protein | Monocytes, macrophages | In a sub-analysis of data from 703 participants of the population-based Tromso study, higher plasma levels of IL-6 were independently associated with plaque progression after a 6-year follow-up (OR 1.4, 95% CI 1.1–1.8 per 1 SD increase in IL-6 level). | Yes (Zithrekimab, Tolcizumab) | (71–74) |

(Continued)
| Biomarker         | Type               | Main source                                      | Key evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Specific target of a drug previously tested in human trials | References |
|-------------------|--------------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-------------|
| CRP               | Protein            | Hepatocytes, white blood cells, adipocytes, smooth muscle cells | In a prospective observational study enrolling 271 participants, higher levels of CRP (quartile 4 vs. 1) were associated with plaque progression after a follow-up of 37 months (OR = 1.8, 95% CI: 1.03–2.99).                                                                                           | No                                                          | (78, 89)    |
| CD36              | Protein            | Various cells including monocytes, endothelial cells, adipocytes, platelets. | In 62 patients with severe carotid stenosis undergoing revascularization, plasma levels of soluble CD36 were higher in those with symptomatic (n = 31) and unstable (echolucent, n = 20) plaques.                                                                                                                                                                                                 | No                                                          | (60)        |
| Lipoprotein (a)   | Lipoprotein        | Food/Liver                                       | In 876 consecutive patients with carotid atherosclerosis (2.5% occlusions), plasma lipoprotein (a) was an independent predictor of carotid occlusion (OR=1.7, 95% CI: 1.2–2.3 per 1 SD increase), suggesting that it plays a role in plaque destabilization/rupture, thrombosis, and impaired fibrinolysis. In 225 patients with coronary artery disease who underwent intra-coronary optical coherence tomography imaging of culprit plaque, the prevalence of thin fibrous cap atheroma was significantly higher in the group with higher serum lipoprotein (a) levels (>25 mg/dL, n=87): 23 vs. 11%. | Yes (AKCEA-Apo(a)-LRx)                                    | (79–81, 90, 91) |
| Non-HDL cholesterol | Lipoproteins     | Food/Liver                                       | In 2,888 patients with carotid plaque, including 1,505 with vulnerable plaques (echolucent, irregular, or ulcerated), higher serum levels of non-HDL cholesterol were independently associated with plaque vulnerability (OR = 1.5 for tertile 3 vs. 1, 95% CI: 1.2–1.8).                                                      | Yes (various class of lipid lowering drugs)                  | (51, 92, 93) |
| Uric acid         | Xanthine (purine derivatives) | Various cells                                     | In a study including 88 patients with carotid plaques (44 symptomatic), serum uric acid levels were significantly higher in patients with symptomatic plaques (7.4 vs. 5.4 mg/dL) who also had higher plaque expression of xanthine oxidase as assessed by immunohistochemistry.                                                                                                                              | Yes (allopurinol)                                           | (62)        |
| Neutrophil count  | Cells              | NA                                               | In 60 patients with recently symptomatic carotid artery disease, higher neutrophil count (>5,900/µL) was associated with detection of microembolic signals on transcranial Doppler monitoring.                                                                                                                                                                                                                                                                  | No                                                          | (58)        |
| miR-199b-3p,      | RNA                | Various cells                                     | In 60 patients with moderate or severe asymptomatic carotid stenosis, higher plasma levels of the micro-RNAs were associated with plaque progression (n = 19) after 2 years of follow-up.                                                                                                                                                                                                                                  | No                                                          | (62)        |
| miR-27b-3p,       | RNA                | Various cells                                     | In 22 patients undergoing carotid endarterectomy, higher levels of miR-200c were found in patients with unstable plaques (echolucent symptomatic) and were positively correlated with biomarkers of plaque instability (matrix metalloproteinase—MMP1, MMP9, interleukin 6, macrophage chemoattractant protein 1—MCP-1).                                                                 | No                                                          | (59, 94)    |
| miR-130a-3p,      | RNA                | Various cells                                     | In an analysis of 165 carotid plaque (67% unstable based on histological criteria), Resistin and chemerin mRNA expression was 80 and 32% lower, respectively, in unstable vs. stable plaques.                                                                                                                                                                                                 | No                                                          | (70)        |
| miR-221-3p,       | RNA                | Various cells                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             |             |
| miR-24-3p         | RNA                | Various cells                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             |             |
| miR-200c          | RNA                | Various cells                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             |             |
| Resistin and      | RNA                | Various cells                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             |             |
| chimerin mRNA     | RNA                | Various cells                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             |             |
NCT03192215) (101), Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS, NCT02427126), and A Study on BMS-986177 (oral factor Xa inhibitor) for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP, NCT03766581) trials will, hopefully, provide conclusive results to guide patient care. Likewise, in the Oxford Vascular Study, a large patent foramen ovale is present in 36% of patients with a cryptogenic stroke aged >60 years (119) and associated with a 2.5 times higher risk of recurrent ischemic stroke (120), thus suggesting it might be worth trialing PFO closure or anticoagulation in elderly patients with a large PFO. However, the causal relationship between the PFO and the recurrent stroke was not formally established and the prevalence of ipsilateral non-stenotic carotid plaque not reported. Because PFO closure or anticoagulation are not expected to prevent strokes due to large vessel atherosclerosis, trials of PFO closure or anticoagulation in elderly patients with a large PFO should carefully plan subgroup analyses according to the presence of alternative candidate causes of the recurrent stroke, notably an atrial cardiopathy or an ipsilateral non-stenotic carotid plaque that may coexist with PFO (43, 44, 121).

Other Therapies and Interventions
Currently, patients with ESUS receive intensive lipid-lowering therapy (e.g., statins, ezetimibe) to achieve a level of LDL cholesterol <70 mg/dL (1.8 mmol/L) as early as possible after stroke (122–124). The treatment is maintained long-term if well-tolerated, even in older adults (125–128). Specific targets of LDL cholesterol have not been assessed in patients with ESUS and it is unknown if the presence of an ipsilateral non-stenotic carotid plaque would modify the effect of lipid-lowering drugs as suggested by findings of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) (129). Furthermore, the potential role of newer classes of lipid-lowering drugs for plaque stabilization and secondary stroke prevention is yet to be defined. Such drugs include proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (small interfering RNA—inclisiran or monoclonal antibodies—evolocumab or alirocumab) and Apo(a) antisense oligonucleotides that reduce plasma levels of both LDL cholesterol and lipoprotein(a) (Lp(a)); as well as anti-angiopoietin-3 monoclonal antibodies that do not affect Lp(a) levels and bempedoic acid (92, 130–135). Like ezetimibe (93, 136), the new lipid-lowering drugs may be useful as add-on or statin-sparing agents in cases of allergy or intolerance to statins, familial hypercholesterolemia, refractory hypercholesterolemia, or in patients with high Lp(a) levels at the time of stroke since statins increase plasma levels of Lp(a) (90, 137). There are reports of an association between high Lp(a) levels and cryptogenic stroke (138, 139) suggesting that Lp(a) could represent a biomarker to guide optimization of lipid-lowering therapy in patients with ESUS as is the case in other cardiovascular diseases.

Systemic inflammation, a hallmark of atherosclerosis, modulates the risk of stroke and the effect of lipid-lowering agents (140–142). This explains the benefit of various anti-inflammatory drugs (e.g., canakinumab, colchicine) for the prevention of atherosclerotic cardiovascular diseases (86, 87, 143). In patients with ESUS and ipsilateral non-stenotic carotid plaque, the effect of anti-inflammatory agents is worth exploring, especially in those with high-risk plaque features since they would not be offered revascularization procedures as first-line treatment according to current guidelines (144–146). Data from the ongoing Colchicine for Prevention of Vascular Inflammation in Non-Cardioembolic Stroke (CONVINCE, NCT02898610) might answer the question of whether patients with ESUS with or without ipsilateral non-stenotic carotid plaques would benefit from the addition of low-dose colchicine to best medical therapy for secondary stroke prevention (147). The relevance of serial vascular imaging to monitor carotid plaque progression and stability is another aspect of the management that remains unexplored.

Besides pharmacological treatments, there is a variety of lifestyle interventions that are beneficial for cardiovascular risk reduction and are recommended by the American Heart Association for secondary stroke prevention no matter the suspected underlying etiology. Such interventions include smoking cessation, regular physical activity, weight loss, improved sleep hygiene, avoidance of noise and air pollution, reduction of salt and sugar intake, higher consumption of fish, fruits, and vegetables (148–155).

CONCLUSION
ESUS is a common subtype of stroke that is frequently associated with an ipsilateral non-stenotic carotid plaque. Evidence suggests that advanced multimodal vascular imaging and biomarkers might help reclassify some ESUS as large vessel strokes. However, the precise algorithm for this reclassification remains to be designed. Despite significant research efforts since the term ESUS was coined in 2014, the optimal management strategy for patients with ESUS remains unclear. There are several ongoing trials investigating various interventions. While waiting for more evidence to support the design of tailored therapeutic guidelines for the various well-phenotyped subgroups of patients with ESUS, clinicians should continue to fully implement guidelines for the various well-phenotyped subgroups of patients with ESUS, clinicians should continue to fully implement all previously validated stroke prevention strategies, whether an ipsilateral non-stenotic carotid plaque is present or not. Such strategies include short-term dual antiplatelet therapy if appropriate, long-term intensive lipid lowering therapy, control of modifiable cardiovascular risk factors (e.g., hypertension, diabetes, smoking, obesity), and lifestyle changes.

AUTHOR CONTRIBUTIONS
JK-T did the literature search and wrote the manuscript. MV and JK-T prepared the figure. AN, SF, DM, GS, TJ, ES, MV, and GJ critically revised the manuscript. All authors approved the final version.

FUNDING
GJ received research grant support from Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation,
REFERENCES

1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. (1993) 24:35–41. doi: 10.1161/01.STR.24.1.35

2. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. (2014) 13:429–38. doi: 10.1016/S1474-4422(13)70310-7

3. Tsvigoulis G, Katsanos AH, Kohrmann M, Caso V, Lemos R, Tsifouk K, et al. Embolic strokes of undetermined source: theoretical construct or useful clinical tool? Ther Adv Neurol Disord. (2019) 12:1756286419851381. doi: 10.1177/1756286419851381

4. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. (2017) 48:867–72. doi: 10.1161/STROKEAHA.116.016414

5. Ntaios G, Perlepe K, Sirimarco G, Strambo D, Eskandari A, Ntaios G, et al. Intracranial carotid plaque with high-risk features in embolic stroke of undetermined source. Stroke. (2017) 52:1121–30. doi: 10.1161/STROKEAHA.117.026286

6. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchihara S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. (2019) 387:2191–201. doi: 10.1056/NEJMoa1812066

7. Ntaios G. Embolic stroke of undetermined source: JACC review topic of the week. J Am Coll Cardiol. (2020) 75:333–40. doi: 10.1016/j.jacc.2019.11.024

8. Li L, Yin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischemic attack and ischemic stroke: a population-based study. Lancet Neurol. (2015) 14:903–13. doi: 10.1016/S1474-4422(15)00132-5

9. Kamtchum-Tatuene J, Ntaios G, Wilman A, Saqqur M, Shuaib A, Jickling GC. Carotid plaques and detection of atrial fibrillation in embolic stroke of undetermined source. Neurology. (2017) 87:665–72. doi: 10.1212/WNL.0000000000002978

10. Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, et al. Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis. Stroke. (2019) 50:2477–85. doi: 10.1161/STROKEAHA.119.025168

11. Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, et al. Rivaroxaban or aspirin for patent foramen ovale and cryptogenic stroke. Neurology. (2016) 87:665–72. doi: 10.1212/WNL.0000000000002978

12. Coutinho JM, Derkatch S, Potvin AR, Tomlinson G, Kiehl TR, Silver FL, et al. Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke. Neurology. (2016) 87:665–72. doi: 10.1212/WNL.0000000000002978

13. Kamtchum-Tatuene J, Noubiap JJ, Wilman AH, Saqqur M, Shuaib A, Jickling GC. Prevalence of high-risk plaques and risk of stroke in patients with asymptomatic carotid stenosis: a meta-analysis. JAMA Neurol. (2020) 77:1018–27. doi: 10.1001/jama.neurol.2020.2658

14. Tao L, Li XQ, Hou XW, Yang BQ, Xia C, Ntaios G, et al. Efficacy and safety of rivaroxaban versus aspirin in patients with cryptogenic stroke. Neurology. (2017) 90:1262–75. doi: 10.1212/WNL.0000000000004353

15. Kamtchum-Tatuene J, O'Donnell MJ, et al. Prevalence and clinical implications. Lancet Neurol. (2019) 18:559–72. doi: 10.1016/S1474-4422(19)30035-3

16. Coutinho JM, Derkatch S, Potvin AR, Tomlinson G, Kiehl TR, Silver FL, et al. Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke. Neurology. (2016) 87:665–72. doi: 10.1212/WNL.0000000000002978

17. Osep JM, Singh N, Marko M, Almekhlafi M, Dowlatshahi D, Puig J, et al. Prevalence of ipsilateral nonstenotic carotid plaques on computed tomography angiography in embolic stroke of undetermined source. Stroke. (2020) 51:1743–9. doi: 10.1161/STROKEAHA.120.029404

18. Fabiani I, Palombo C, Caramella D, Nilsson J, De Caterina R. Imaging of the vulnerable carotid plaque: role of imaging techniques and a research agenda. Neurology. (2020) 94:922–32. doi: 10.1212/25WNL.0000000000009480

19. Suppes SA, Brotman DJ, Hooper KW, Gage BF, Sacco RL, et al. Intraobserver and interobserver agreement among stroke severity and severity rating. Neurology. (2017) 90:1262–75. doi: 10.1212/WNL.0000000000004353

20. Karagkiozi E, et al. Carotid plaques and detection of atrial fibrillation in patients with cryptogenic stroke. Neuroimaging Clin N Am. (2016) 26:97–110. doi: 10.1016/j.nic.2015.09.008

21. Kiely PJ, Camps-Renom P, Giannotti N, Marti-Fabregas J, McNulty JP, Baron JC, et al. A risk score including carotid plaque inflammation and stenosis severity improves identification of recurrent stroke. Stroke. (2020) 51:838–45. doi: 10.1161/STROKEAHA.119.027268

22. Badaradan H, Gupta A. Extracranial vascular disease: carotid stenosis and plaque imaging. Neuroimaging Clin N Am. (2021) 31:157–66. doi: 10.1016/j.nic.2021.02.002

23. Ringelstein EB, Droste DW, Babikian LV, Evans DH, Grosset DG, Kaps M, et al. Consensus on microembolus detection by TCD. International Consensus Group on Microembolus Detection. Stroke. (1998) 29:725–9. doi: 10.1161/01.STR.29.3.725

24. Saam T, Ferguson MS, Yarnyk VL, Takaya N, Xu D, Polissar NL, et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol. (2005) 25:234–9. doi: 10.1161/01.ATV.20.4.1155238

25. Markus HS, Harrison MJ. Estimation of cerebrovascular reactivity using transcranial Doppler, including the use of breath-holding as the vasodilatory stimulus. Stroke. (1992) 23:668–73. doi: 10.1161/01.STR.23.5.668

26. Rafailidis V, Li X, Siddhu PS, Partovi S, Staub D. Contrast imaging ultrasound for the detection and characterization of carotid vulnerable plaque. Cardiovasc Diagn Ther. (2020) 10:965–81. doi: 10.21037/cdt.2020.01.08

27. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. (2000) 20:1177–8. doi: 10.1161/01.ATV.20.5.1177

28. Virmani R, Kologdie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. (2000) 20:1202–7. doi: 10.1161/01.ATV.20.5.1262
34. Saba L, Brinjikji W, Spence JD, Wintermark M, Castillo M, Borst GD, et al. Roadmap consensus on carotid artery plaque imaging and impact on therapy strategies and guidelines: an international, multispecialty, expert review and position statement. AJNR Am J Neuroradiol. (2021). doi: 10.3174/ajnr.A7223. [Epub ahead of print]

35. Bayer-Karpinska A, Schwarz W, Wollenweber FA, Poppert H, Boeckh-Behren T, Becker A, et al. The carotid plaque imaging in acute stroke (CAPLAS) study: protocol and initial baseline data. BMC Neurol. (2013) 13:201. doi: 10.1186/1471-2373-13-201

36. Freilinger TM, Schindler A, Schmidt C, Grimm J, Cyran C, Schwarz F, et al. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. JACC Cardiovasc Imaging. (2012) 5:397–405. doi: 10.1016/j.jcmg.2012.01.012

37. Hyafil F, Schindler A, Schmidt C, Grimm J, Cyran C, Schwarz F, et al. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. JACC Cardiovasc Imaging. (2012) 5:397–405. doi: 10.1016/j.jcmg.2012.01.012

38. Grosse GM, Sieweke JT, Biber S, Ziegler NL, Gabriel MM, Schuppers PH, et al. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. (2007) 27:15–26. doi: 10.1161/01.ATV.0000251503.35795.4f

39. Kopczak A, Schindler A, Bayer-Karpinska A, Koch ML, Sepp D, Zeller J, et al. Complicated carotid artery plaques as a cause of cryptogenic stroke. J Am Coll Cardiol. (2020) 76:2212–22. doi: 10.1016/j.jacc.2020.09.532

40. Sun J, Underhill HR, Hippe DS, Xue Y, Yuan C, Hatsukami TS. Sustained acceleration in carotid atherosclerotic plaque progression with intraplaque hemorrhage: a long-term time course study. JACC Cardiovasc Imaging. (2012) 5:798–804. doi: 10.1016/j.jcmg.2012.03.014

41. Grosse GM, Sieweke JT, Biber S, Ziegler NL, Gabriel MM, Schuppers PH, et al. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. (2007) 27:15–26. doi: 10.1161/01.ATV.0000251503.35795.4f

42. Ameriso SF, Amarenco P, Pearce LA, Perera KS, Ntaios G, et al. High levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 are associated with carotid plaque inflammation. Circulation. (2018) 138:E91–8. doi: 10.1161/CIRCULATIONAHA.118.035864

43. Ntafos G, Sagris B, Strambo D, Perleke K, Sirimarco G, Georgiopoulous G, et al. Carotid atherosclerosis and patent foramen ovale in symptomatic stroke of undetermined source: interplay of arterial and atrial disease. Stroke. (2020) 51:3737–41. doi: 10.1161/STROKEAHA.120.030537

44. Jaffe A, Guidolin B, Rudaevs JB, Nasr N, Larrue V. Non-obstructive carotid atherosclerosis and patent foramen ovale in young adults with cryptogenic stroke. J Stroke Cerebrovasc Dis. (2020) 29:104936. doi: 10.1016/j.jstrokecerebrovasdis.2020.104936

45. Jiao Y, Qin Y, Zhang Z, Zhang H, Liu H, Li C. Early identification of carotid vulnerable plaque in asymptomatic patients with ultrasound-determined carotid atherosclerotic plaque instability. Front. Neurol. (2021) 12:622869. doi: 10.3389/fneur.2021.622869

46. Behrens T, Miranda MM, Sieweke JT, Biber S, Ziegler NL, Gabriel MM, et al. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. (2007) 27:15–26. doi: 10.1161/01.ATV.0000251503.35795.4f

47. Skjelland M, Michelsen AE, Krohg-Sorensen K, Tenneø B, Dahl A, Bakke S, et al. Plasma levels of glycanse B are increased in patients with lipid-rich carotid plaques as determined by echogenicity. Atherosclerosis. (2007) 195:142–6. doi: 10.1016/j.atherosclerosis.2007.05.001

48. Nasr N, Rudaevs JB, Arnal JF, Sie P, Larrue V. Association of neutrophil count with microembolization in patients with symptomatic carotid artery stenosis. Atherosclerosis. (2009) 207:519–23. doi: 10.1016/j.atherosclerosis.2009.05.003

49. Jiao Y, Qin Y, Zhang Z, Zhang H, Liu H, Li C. Early identification of carotid vulnerable plaque in asymptomatic patients. BMC Cardiovasc Disord. (2020) 20:429. doi: 10.1186/s12872-020-01709-5

50. Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sorensen K, Russell D, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. (2008) 39:3092–5. doi: 10.1161/STROKEAHA.108.517128

51. Georgakis MK, van der Laan SW, Asare Y, Mekke JM, Hattijema S, Schoneveld AH, et al. Monocyte-chemotactant protein-1 levels in human atherosclerotic lesions associate with plaque vulnerability. Arterioscler Thromb Vasc Biol. (2021) 1:2038–48. doi: 10.1161/ATVBAHA.121.316091

52. Dolz S, Gorriz D, Tembl JI, Sanchez D, Fortea G, Parkhutik V, et al. Circulating microRNAs as novel biomarkers of stenosis progression in asymptomatic carotid stenosis. Stroke. (2017) 48:10–6. doi: 10.1161/STROKEAHA.116.013650

53. Basic I, Stojkovic S, Assadian A, Rauscher S, Duschek N, Kaun C, et al. The relevance of vascular endothelial growth factor, hypoxia inducible factor alpha, and clusterin in carotid plaque instability. J Stroke Cerebrovasc Dis. (2019) 28:1540–5. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.009

54. Ammirati E, Moroni FD, Magnoni M, Camici PG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. (2015) 2015:781329. doi: 10.1155/2015/781329

55. Xiao J, Chen L, Melander O, Parkhutik V, et al. Circulating microRNAs as novel biomarkers of stenosis progression in asymptomatic carotid stenosis. Stroke. (2017) 48:10–6. doi: 10.1161/STROKEAHA.116.013650

56. Alhazmi H, Bani-Sadr A, Bochaton T, Paccalet A, Da Silva CC, Buisson M, et al. Large vessel cardioembolic stroke and embolic stroke of undetermined source: the Northern Manhattan Study. J Neurology. (2017) 264:135–42. doi: 10.1007/s00415-016-8397-9

57. Kamtchum-Tatuene J, Jickling GC. Blood biomarkers for stroke diagnosis and management. NeuroMolecular Med. (2019) 21:344–68. doi: 10.1002/an.21017-019.08530-0

58. Jickling GC, Xu H, Stamova B, Ander BP, Zhan X, Tian Y, et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol. (2010) 68:861–92. doi: 10.1002/ana.22187
86. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. (2017) 377:1119–31. doi: 10.1056/NEJMoa1707914
87. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. (2016) 118:145–56. doi: 10.1161/CIRCRESAHA.115.306656

Kamtchum-Tatuene et al. Non-stenotic Carotid Plaques in ESUS

88. Ridker PM. Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis. Circ Res. (2019) 124:437–50. doi: 10.1161/CIRCRESAHA.118.313129

89. Kamtchum-Tatuene J, Jickling GC. Letter by Kamtchum-Tatuene and Jickling Regarding Article, “Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy”. Stroke. (2021) 52:e64–5. doi: 10.1161/STROKEAHA.120.032699

90. Kamtchum-Tatuene J, Jickling GC. Letter by Kamtchum-Tatuene and Jickling Regarding Article, “Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy”. Stroke. (2021) 52:e64–5. doi: 10.1161/STROKEAHA.120.032699

91. Tsakas R, Kavvatzou-Prokopczak E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhegen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. (2020) 382:244–54. doi: 10.1056/NEJMoa1905239

92. Hegele RA, Tsakas R. Lipid-lowering agents. Circ Res. (2019) 124:386–404. doi: 10.1161/CIRCRESAHA.118.313171

93. Yoshida ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. (2019) 381:1557–67. doi: 10.1056/NEJMra1806939

94. Magenta A, Sileno S, D’Agostino M, Persiani F, Beji S, Paolini A, et al. Atheroprotection in carotid arteries: miR-200c as a promising biomarker. Clin Sci. (2018) 132:2423–36. doi: 10.1042/CS20180684

95. Putaala J, Martinez-Majander N, Saeed S, Yesilot N, Jakala P, Nerg O, et al. Searching for explanations for cryptogenic stroke in the young: revealing the triggers, causes, and outcome (SECRETO): rationale and design. Eur Stroke J. (2018) 24:1141–5. doi: 10.1161/STROKEAHA.120.032698

96. Ricci B, Chang AD, Hemendinger M, Dakay K, Cutting S, Burton T, et al. A simple score that predicts paraoxysmal atrial fibrillation on outpatient cardiac monitoring after embolic stroke of unknown source. J Stroke Cerebrovasc Dis. (2020) 29:104604. doi: 10.1016/j.jstrokecerebrovasdis.2019.104604

97. Ntaios G, Perlepe K, Lambrou D, Sirimarco G, Strambo D, Eskandari A, et al. Identification of patients with embolic stroke of undetermined source and low risk of new incident atrial fibrillation: the AF-ESUS score. Int J Stroke. (2021) 16:29–38. doi: 10.1177/1747493020992528

98. Kang Z, Kamtchum-Tatuene J, Li M, Jickling GC. Cardiac natriuretic peptides for diagnosis of covert atrial fibrillation after acute ischaemic stroke: a meta-analysis of diagnostic accuracy studies. Stroke Vasc Neurol. (2020) 5:128–32. doi: 10.1136/svn-2020-000440

99. Goyal M, Singh N, Marko M, Hill MD, Menon BK, Demchuk AM, et al. Embolic stroke of undetermined source and symptomatic nonstenotic carotid disease. Stroke. (2020) 51:1321–3. doi: 10.1161/STROKEAHA.119.028853

100. Strambos D, Sirimarco G, Nannoni S, Perlepe K, Ntaios G, Vennemos K, et al. Embolic stroke of undetermined source and patent foramen ovale: risk...
of paradoxical embolism score validation and atrial fibrillation prediction. *Stroke.* (2021) 52:1643–52. doi: 10.1161/STROKEAHA.120.032453

105. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm J, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. *N Engl J Med.* (2018) 379:215–25. doi: 10.1056/NEJMoa1800410

106. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med.* (2013) 369:11–9. doi: 10.1056/NEJMoa1215340

107. Lee M, Safer JL, Hong KS, Rao NM, Wu YL, Ovbiagele B. antiplatelet regimen for patients with breakthrough strokes while on aspirin: a systematic review and meta-analysis. *Stroke.* (2017) 48:2610–3. doi: 10.1161/STROKEAHA.117.017895

108. Pan Y, Elm J, Li H, Easton JD, Wang Y, Farrant M, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trials. *JAMA Neurol.* (2019) 76:1466–73. doi: 10.1001/jamanetworkneuro.2019.2531

109. Dammann P, Woudstra P, Kuijt WJ, de Winter RJ, James SK. P2Y12 platelet inhibition in clinical practice. *J Thromb Thrombolysis.* (2012) 33:143–53. doi: 10.1007/s11239-011-0667-5

110. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Circulation.* (2017) 135:21–33. doi: 10.1161/CIRCULATIONAHA.116.024913

111. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. *N Engl J Med.* (2020) 383:207–17. doi: 10.1056/NEJMoa1916870

112. Xiong Y, Bath PM. Antiplatelet therapy for transient ischaemic attack. *Lancet.* (2012) 379:3207–18. doi: 10.1016/S0140-6736(12)61730-2

113. Li ZX, Xiong Y, Gu HQ, Fisher M, Xian Y, Johnston SC, Wang YJ. Antiplatelet regimen for patients with breakthrough strokes while on aspirin: a systematic review and meta-analysis. *Stroke.* (2021) 52:2521–9. doi: 10.1161/STROKEAHA.120.030089

114. Lin WV, Vickers A, Callahan A, Goldstein LB, Zivin J, et al. Atrorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. *Stroke.* (2008) 39:3297–302. doi: 10.1161/STROKEAHA.108.516450

115. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med.* (2015) 372:1590–9. doi: 10.1056/NEJMoa1500838

116. Schwartz GG, Steg PG, Sarek M, Bhatt DL, Bittner V, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med.* (2018) 379:2097–107. doi: 10.1056/NEJMoa1801174

117. Julius U, Tsilimis S, Schatz U, Fischer S, Bornstein SR, Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. *Clin Res Cardiol Suppl.* (2019) 14:45–50. doi: 10.1177/117879–019-00099–z

118. Rosenson RS, Burgess LJ, Ebenbichler CE, Baum SJ, Stroes EGS, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. *N Engl J Med.* (2020) 383:2307–19. doi: 10.1056/NEJMoa2031049

119. Ruscica M, Zimetti F, Adorni MP, Sirtori CR, Lupo MG, Ferri N. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherosclerotic dyslipidemia. *Pharmacol Res.* (2015) 103:104653. doi: 10.1016/j.phrs.2015.10.4653

120. Di Minno A, Lupoli R, Calcaterra I, Poggio P, Forte F, Spadarella G, et al. Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc.* (2020) 9:e016262. doi: 10.1161/JAHA.119.016262

121. Awad K, Mkhailidis DP, Katsiki N, Muntner P, Banach M, Lipid, Blood Pressure Meta-Analysis Collaboration Group. Effect of ezetimibe monotherapy on plasma Lipoprotein(a) concentrations in patients with primary hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials. *Drugs.* (2018) 78:453–62. doi: 10.1007/s40265-018-0870-1

122. Tsikvidis S, Gordts P, Nura C, Yeang C, Witzum JL. Statin therapy increases lipoprotein(a) levels. *Eur Heart J.* (2020) 41:2275–84. doi: 10.1093/eurheartj/ehz310

123. Beheshtian A, Shiote SG, Segal AZ, Leifer D, Tracy RP, Rader DJ, et al. Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. *Atherosclerosis.* (2016) 253:57–53. doi: 10.1016/j.atherosclerosis.2016.08.013

124. Lin WV, Vickers A, Prospero Ponce CM, Lee AG. Elevated lipoprotein(a) levels as the cause of cryptogenic stroke in a young Ashkenazi Jewish female. *Can J Ophthalmol.* (2019) 54:e126–8. doi: 10.1016/j.jcjo.2018.07.011
140. Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol. (2016) 12:594–604. doi: 10.1038/nrneurol.2016.125

141. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. (2019) 5:56. doi: 10.1038/s41572-019-0106-z

142. Puri R, Nissen SE, Arsenault BJ, Deanfield J, Bittencourt MS, et al. Effect of C-reactive protein on Lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial. JAMA Cardiol. (2020) 5:1136–43. doi: 10.1001/jamacardio.2020.2413

143. Lawler PR, Bhatt DL, Godoy LC, Luscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. (2021) 42:113–31. doi: 10.1093/eurheartj/ehaa099

144. Brett TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. J Am Coll Cardiol. (2011) 57:1002–44. doi: 10.1016/j.jacc.2010.11.005

145. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor’s Choice - management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. (2018) 55:3–81. doi: 10.1016/j.ejvs.2017.06.021

146. Bonati LH, Kakko S, Berkefeld J, de Borst GJ, Bulbulia R, Halliday A, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. Eur Stroke J. (2021) 6:1–XLVII. doi: 10.1177/23969873211026990

147. Katsanos AH, Palaiodimou L, Price C, Giannopoulos S, Lemmens R, Kosmidou M, et al. Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. Eur J Neurol. (2020) 27:1035–8. doi: 10.1111/ene.14198

148. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline. From the American Heart Association/American Stroke Association. Stroke. (2021) 52:e364–467. doi: 10.1161/STR.0000000000000375

149. Rippe JM. Lifestyle strategies for risk factor reduction, prevention, and treatment of cardiovascular disease. Am J Lifestyle Med. (2019) 13:204–12. doi: 10.1177/1559876188123995

150. Munzel T, Sorensen M, Daiber A. Transportation noise pollution and cardiovascular disease. Nat Rev Cardiol. (2021) 18:619–36. doi: 10.1038/s41569-021-00532-5

151. Munzel T, Sorensen M, Gori T, Schmidt FP, Rao X, Brook FR, et al. Environmental stressors and cardio-metabolic disease: part II-mechanistic insights. Eur Heart J. (2017) 38:557–64. doi: 10.1093/eurheartj/ehw294

152. Munzel T, Sorensen M, Gori T, Schmidt FP, Rao X, Brook J, et al. Environmental stressors and cardio-metabolic disease: part I-epidemiologic evidence supporting a role for noise and air pollution and effects of mitigation strategies. Eur Heart J. (2017) 38:530–6. doi: 10.1093/eurheartj/ehw269

153. McAlpine CS, Kiss MG, Rattik S, He S, Vassalli A, Valet C, et al. Sleep modulates haematopoiesis and protects against atherosclerosis. Nature. (2019) 566:383–7. doi: 10.1038/s41586-019-0948-2

154. Leng Y, Cappuccio FP, Wainwright NW, Surtees PG, Luben R, Brayne C, et al. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. Neurology. (2015) 84:1072–9. doi: 10.1212/WNL.0000000000001371

155. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. (2018) 378:e34. doi: 10.1056/NEJMoa1800389

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kamtchum-Tatuene, Nomani, Falciene, Munsterman, Sykes, Joy, Sprock, Vargas and Jickling. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.